# A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)

> **NCT02156804** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1009 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Nivolumab (BMS-936558)

## Key facts

- **NCT ID:** NCT02156804
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-07
- **Primary completion:** 2019-01-18
- **Final completion:** 2019-01-18
- **Target enrollment:** 1009 (ACTUAL)
- **Last updated:** 2020-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02156804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02156804, "A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02156804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*